FibroGen Announces Completion of Patient Enrollment in LELANTOS-2, a Phase III Clinical Study of Pamrevlumab in Duchenne Muscular Dystrophy

FibroGen, Inc. announced completion of patient enrollment for LELANTOS-2, a Phase III clinical study of pamrevlumab in patients with ambulatory Duchenne muscular dystrophy.
[FibroGen, Inc.]
Press Release
spot_img

Stay up-to-date with your field!

Subscribe for free weekly science newsletters.

Related News